Targeting NFκB signaling in GD2+ BCSCs

Nguyen, Khoa; Battula, V. Lokesh

doi:10.18632/aging.101274

Search citation statements

Order By: Relevance

Paper Sections

Select...

Nf-κb Signaling In the Regulation Of Gd3 Synthase1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 7 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…72 NF-κB regulates ST8SIA1, the gene for GD3 synthase (Fig. 3), 73 and Nguyen et al 74 found that NF-κB signaling is one of the most highly activated pathways in GD2 + BCSCs. Inhibition of this pathway by genetic or pharmacological methods markedly inhibited GD2 and GD3 synthase expression in TNBC cell lines.…”

Section: Nf-κb Signaling In the Regulation Of Gd3 Synthasementioning

confidence: 95%

Ganglioside GD2: a novel therapeutic target in triple‐negative breast cancer

Shao

Anand

Andreeff

et al. 2021

Annals NY Academy of Science

View full text Add to dashboard Buy / Rent full text

Triple-negative breast cancer (TNBC) is a heterogeneous disease characterized by lack of hormone receptor expression and is known for high rates of recurrence, distant metastases, and poor clinical outcomes. TNBC cells lack targetable receptors; hence, there is an urgent need for targetable markers for the disease. Breast cancer stem-like cells (BCSCs) are a fraction of cells in primary tumors that are associated with tumorigenesis, metastasis, and resistance to chemotherapy. Targeting BCSCs is thus an effective strategy for preventing cancer metastatic spread and sensitizing tumors to chemotherapy. The CD44 hi CD24 lo phenotype is a well-established phenotype for identification of BCSCs, but CD44 and CD24 are not targetable markers owing to their expression in normal tissues. The ganglioside GD2 has been shown to be upregulated in primary TNBC tumors compared with normal breast tissue and has been shown to identify BCSCs. In this review, we discuss GD2 as a BCSC-and tumor-specific marker in TNBC; epithelial-to-mesenchymal transition and the signaling pathways that are upstream and downstream of GD2 and the role of these pathways in tumorigenesis and metastasis in TNBC; direct and indirect approaches for targeting GD2; and ongoing clinical trials and treatments directed against GD2 as well as future directions for these strategies.

show abstract

Targeting NFκB signaling in GD2+ BCSCs

Cited by 1 publication

References 7 publications

Ganglioside GD2: a novel therapeutic target in triple‐negative breast cancer

Contact Info

Product

Resources

About